Very-high-risk localized prostate cancer: definition and outcomes
- PMID: 24189998
- PMCID: PMC3945953
- DOI: 10.1038/pcan.2013.46
Very-high-risk localized prostate cancer: definition and outcomes
Abstract
Background: Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially-some will have excellent cancer-specific survival, whereas others will experience early metastasis even after aggressive local treatments. Current nomograms, which yield continuous risk probabilities, do not separate high-risk PCa into distinct sub-strata. Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy.
Methods: We queried the Johns Hopkins radical prostatectomy database to identify 753 men with NCCN high-risk localized PCa (Gleason sum 8-10, PSA >20 ng ml(-1), or clinical stage ≥T3). Twenty-eight alternate permutations of adverse grade, stage and cancer volume were compared by their hazard ratios for metastasis and cancer-specific mortality. VHR criteria with top-ranking hazard ratios were further evaluated by multivariable analyses and inclusion of a clinically meaningful proportion of the high-risk cohort.
Results: The VHR cohort was best defined by primary pattern 5 present on biopsy, or ≥5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. These criteria encompassed 15.1% of the NCCN high-risk cohort. Compared with other high-risk men, VHR men were at significantly higher risk for metastasis (hazard ratio 2.75) and cancer-specific mortality (hazard ratio 3.44) (P<0.001 for both). Among high-risk men, VHR men also had significantly worse 10-year metastasis-free survival (37% vs 78%) and cancer-specific survival (62% vs 90%).
Conclusions: Men who meet VHR criteria form a subgroup within the current NCCN high-risk classification who have particularly poor oncological outcomes. Use of these characteristics to distinguish VHR localized PCa may help in counseling and selection optimal candidates for multimodal treatments or clinical trials.
Conflict of interest statement
None
Figures
Comment in
-
Prostate cancer: The high-risk dichotomy.Nat Rev Urol. 2014 Jan;11(1):2. doi: 10.1038/nrurol.2013.284. Epub 2013 Nov 26. Nat Rev Urol. 2014. PMID: 24276081 No abstract available.
Similar articles
-
Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):254-62. doi: 10.1016/j.ijrobp.2015.10.056. Epub 2015 Oct 31. Int J Radiat Oncol Biol Phys. 2016. PMID: 26853334 Free PMC article.
-
Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.Cancer. 2019 Feb 1;125(3):391-397. doi: 10.1002/cncr.31833. Epub 2018 Nov 13. Cancer. 2019. PMID: 30423193
-
Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.J Urol. 2022 Feb;207(2):375-384. doi: 10.1097/JU.0000000000002250. Epub 2021 Sep 24. J Urol. 2022. PMID: 34555930
-
Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22373045 Free PMC article.
-
Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3. BJU Int. 2017. PMID: 28464446
Cited by
-
Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.Curr Treat Options Oncol. 2024 Jan;25(1):66-83. doi: 10.1007/s11864-023-01162-4. Epub 2024 Jan 3. Curr Treat Options Oncol. 2024. PMID: 38212510 Review.
-
Ultra-High Prostate-Specific Antigen Level: A Potential Very-High-Risk Factor for Localized High-Risk Prostate Cancer.Cancers (Basel). 2023 Nov 29;15(23):5644. doi: 10.3390/cancers15235644. Cancers (Basel). 2023. PMID: 38067349 Free PMC article.
-
Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients.J Robot Surg. 2023 Oct;17(5):2441-2449. doi: 10.1007/s11701-023-01670-3. Epub 2023 Jul 19. J Robot Surg. 2023. PMID: 37466903
-
Management of Localized Prostate Cancer in Men With Human Immunodeficiency Virus: Analysis of a Large Retrospective Cohort.Clin Genitourin Cancer. 2023 Oct;21(5):614.e1-614.e8. doi: 10.1016/j.clgc.2023.04.012. Epub 2023 Apr 29. Clin Genitourin Cancer. 2023. PMID: 37208248
-
Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma.Adv Radiat Oncol. 2022 Mar 10;7(6):100935. doi: 10.1016/j.adro.2022.100935. eCollection 2022 Nov-Dec. Adv Radiat Oncol. 2022. PMID: 36420198 Free PMC article.
References
-
- D’Amicoa V, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick Ga, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969–74. - PubMed
-
- Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE) The Journal of urology. 2005 May;173(5):1557–61. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
